Alex Shaw

Have you heard of biosimilars as a treatment for Inflammatory Bowel Disease? Biosimilars are medications that closely replicate the structure and function of original biologic drugs.  How are #biosimilars approved and are they a safe and effective solution?  Chris Ma, MD, MPH, FRCPC answers all you need to know in our latest reel! Learn more about biosimilars as a treatment for IBD: https://lnkd.in/eAz7B7BJ #IBD #DigestiveHealth

22

A panel of experts, led by Ryan Haumschild PharmD, MS, MBA, CPEL, discuss the impact chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have on patient quality of life and explore current treatment strategies in CLL and SLL management. Watch the series here: https://bit.ly/4aXuhr2  #CancerCare

5

In 2024, 5 emerging BTK inhibitors are undergoing late-phase clinical investigation for #multiplesclerosis. Most clinicians are likely unaware of the clinical data regarding their use in MS. Dive into the data and earn free #CME here: https://bit.ly/4gViIVp #MedEd #FOAMed

2

Can BTK inhibitors tackle cancer and autoimmunity? 🤔 💊 BTK inhibitors are a class of drugs that were initially developed to control the spread of cancer. Now, they are in the running to treat a host of autoimmune diseases.  Currently, Sanofi and Novartis’ drugs seem to be making progress in the clinic. 🏥 But that’s not to say that everything is going well in the field. These drugs have led to serious side effects in patients. 🤒 Read our latest article to find out more about these cancer drugs that are emerging as autoimmune therapies! 👇 https://lnkd.in/dqbBJ8nv #BTKinhibitors #cancertreatment #autoimmunetherapies #medicalresearch #drugdevelopment #healthcareadvancements InnoCare (HKEX: 09969; SSE: 688428) | Biogen | Merck | Gossamer Bio | Oncternal Therapeutics | Johnson & Johnson | AbbVie | Eli Lilly and Company | Loxo@Lilly | AstraZeneca | BeiGene

1

Are your #MedicalAffairs teams reaching all the providers who need your support? Learn how to transform your outreach strategies with data-driven insights powered by real-world patient journey data. Read more. ⬇️

7

Biosimilars were introduced to the market for more patient access. JAMA, Journal of the American Medical Association conducted a study finding that hasn't been entirely the case. The underlying cause? It's mostly traced back to commercial insurance claims. It has ended up that many patients have paid more for a biosimilar than for the name brand drug. This is correlated to formularies and insurance being paid a portion of the list price. Patients deserve to know what #Rx is covered, for how much, and why. Actions to increase access to care should deliver the intent. This should be less about profit, and more about enacting good for healthcare outcomes. Thank you to STAT for thoroughly covering this story. https://lnkd.in/e9c_ZVV8

7

Really interesting data for benralizumab in eosinophilic esophagitis (EoE), underscoring some of the challenges there are with treating this condition. The data show histologic improvement, but this did not necessarily lead to improvement in symptoms. While the data suggest an uncertain future for benralizumab in EoE, they are nevertheless useful in highlighting that success in EoE treatment must include improvement in symptoms. Fortunately, EoE patients have received a few new treatment options over the past couple of years with the approvals of DUPIXENT® (dupilumab) HCP (a biologic) and Eohilia (a steroid). #gastroenterology #clinicaldata

6

Define the difference between Biosimilars and Generics with Tedra Gray, MSN, APRN, ACNP-BC! Tune into this FAQ to compare the composition of Biosimilars and Generic drugs at https://loom.ly/MYGBcZc 💊

9

1 Comment

BMS is poised to enter the Eosinophilic Esophagitis (EoE) market. Buried in the BMS Q2 2024 earnings call was news that company's eosinophilic esophagitis (EoE) treatment, cendakimab, successfully met Phase 3 clinical endpoints. Similar to already-approved, Dupixent, cendakimab is a biologic with subcutaneous injections every other week. Specifics on the data have yet to be released, this new agent could pose some competitive pressure for Dupixent in EoE. #gastroenterology #clinicaldata https://lnkd.in/g_2a2MWv

9

🚀 𝗧𝗵𝗲 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝗶𝘀 𝗲𝘃𝗼𝗹𝘃𝗶𝗻𝗴, and the 2024 ZS Medical Affairs Outlook Report highlights key trends shaping the field! 🔹 𝗛𝘆𝗯𝗿𝗶𝗱 𝗞𝗢𝗟 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁: Key Opinion Leaders now expect a mix of virtual and in-person interactions, reshaping MSL operations. 🔹 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝗠𝗦𝗟𝘀: Field medical roles, like MSLs, are expanding as organizations recognize their strategic value. 🔹 𝗔𝗜 & 𝗗𝗮𝘁𝗮 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀: Generative AI is transforming data insights and management. 🔹 𝗘𝗮𝗿𝗹𝘆-𝗣𝗵𝗮𝘀𝗲 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁: Building relationships with KOLs before Phase 3 trials is critical for product success. At The MSL Academy™, we're dedicated to guiding MSLs in embracing these changes and enhancing their impact on healthcare. 💡 #MedicalAffairs #MSL #AI #HealthcareLeadership #HybridEngagement #KOL #ClinicalResearch #medicalaffairs #KOLs #KOLEngagement #Pharma #Biotech #MSL #MedicalSacienceLiaison #medical #clinicalresearch #mslcareers

1

The time is now for PBMs to prioritize coverage of lower-priced #generics and #biosimilars. Learn how this is not the current practice and dive into our analysis that helps to explain the “why.” https://lnkd.in/ewiw3bYD

9